PDE5 inhibitors: breaking new grounds in the treatment of COVID-19.

Ryan VargheseGargi DigholkarJainam KarsiyaSahil SalviJeenam ShahDileep Kumar Rohit Sharma

Published in: Drug metabolism and personalized therapy (2023)

These benefits of PDE5 inhibitors make it a potential drug in the physicians' armamentarium in alleviating symptoms associated with SARS-CoV-2 infection. However, adequate clinical studies must be instituted to eliminate any untoward adverse events.

Keyphrases

coronavirus disease
sars cov
primary care
respiratory syndrome coronavirus
physical activity
combination therapy
climate change
replacement therapy